Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab in Cetuximab-Refractory Metastatic Colorectal Cancer
NCT01801904Phase 2Unknown
- Sponsor
- National Cancer Institute
- Start
- Dec 2012
- Primary completion
- Dec 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of panitumumab in metastatic colorectal cancer (mCRC), sponsored by National Cancer Institute. Status: unknown.
02
Drugs
panitumumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01801904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01801904.